Latest GeoVax News
GeoVax Presenting at Upcoming Scientific Conferences
Plug & Play Platform Continues to be Recognized for Distinct Benefits
ATLANTA, GA, November 7, 2018 – GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company specializing in developing human vaccines, announced today that it will be represented during presentations at the following upcoming scientific conferences.
Fourth International Conference on Vaccines Research and Development, Baltimore, Nov. 12-14
Farshad Guirakhoo, PhD, GeoVax Chief Scientific Officer, will deliver an oral presentation entitled, Development of Vaccines for Infectious Diseases and Cancer Using a Novel MVA-VLP “Plug & Play” Vector Platform; Preclinical Efficacy for Ebola, Lassa Fever and Zika as examples for single dose vaccines. In this talk, the most relevant single-dose vaccine efficacy data, including characterization of humoral and T cell responses, for three different pathogens (Ebola, Lassa and Zika) will be presented as examples for a broad utility of the platform for other indications such as malaria, HPV, HBV and cancer immunotherapy. Dr. Guirakhoo will also serve as Chair for the conference breakout session on Emerging and Re-emerging Diseases on November 14.
World Vaccine & Immunotherapy Congress, San Diego, Nov. 28-30
During this conference, Dr. Guirakhoo will deliver an oral presentation entitled, A Novel Approach for Developing Single Dose and Safe Vaccines for Emerging Infectious Diseases. In this talk, data for Ebola, Lassa and Zika vaccines, pathogens selected from three different families of viruses, will demonstrate GeoVax’s capability of developing safe and effective single-dose vaccines for many known emerging and re-emerging diseases, as well as for pathogens currently unknown to cause human disease (“Disease X”) with potential for a serious international epidemic. Many of these are included in the “Blueprint List of Priority Diseases” published by the World Health Organization (WHO); with explicit and urgent calls by WHO for accelerated research and development for vaccines and therapeutics.
GeoVax Labs, Inc., is a clinical-stage biotechnology company developing human vaccines against infectious diseases using its MVA-VLP vaccine platform. GeoVax was the winner of the 2018 “Best Biotech” Vaccine Industry Excellence Awards, a finalist for the 2018 “Best Prophylactic Vaccine” Award for its Zika vaccine at the World Vaccine Congress, as well as a finalist for Pipelines of Promise at Buzz of Bio 2018. The Company’s development programs are focused on vaccines against HIV, Zika, hemorrhagic fever viruses (Ebola, Sudan, Marburg, Lassa) and malaria. GeoVax also is evaluating the use of its MVA-VLP platform in cancer immunotherapy, and for therapeutic use in chronic Hepatitis B infections. GeoVax’s vaccine platform supports in vivo production of non-infectious VLPs from the cells of the very person receiving the vaccine. The production of VLPs in the person being vaccinated mimics virus production in a natural infection, stimulating both the humoral and cellular arms of the immune system to recognize, prevent, and control the target infection. For more information, visit www.geovax.com.